10-Q · May 6, 2026
Taysha Gene Therapies reported a disappointing Q1 2026 performance with zero revenue compared to $2.302 million in the same period of the prior year, while losses widened to $42.4 million from $21.5 million. The…
Earnings analysis · 10-Q
TSHA earnings analysis
Filed August 11, 2026 · Our reading of the company's report
The latest report
Taysha’s Q2 2026 results were weak financially, with $0 revenue, diluted EPS of -$0.13, and a $46.6 million net loss versus consensus revenue of $618,180 and EPS of -$0.11. Clinical progress continued across 33 patients…
Read full summary
Taysha’s Q2 2026 results were weak financially, with $0 revenue, diluted EPS of -$0.13, and a $46.6 million net loss versus consensus revenue of $618,180 and EPS of -$0.11. Clinical progress continued across 33 patients without severe treatment-related SAEs or DLTs, and a $230.0 million financing extended cash runway into 2H 2028. The SEC investigation was terminated in June 2026, but unresolved derivative litigation and continued dependence on 2027 clinical and regulatory milestones keep the overall outlook neutral.
Gross and operating margin
How much of each revenue dollar the business keeps.
One point per quarterly or annual filing. Both margins are shares of that report's revenue.
How we read each report
Our analysis across the last few reports.
Our model's reading of each filing, not the share price or the market's reaction. Annual and quarterly reports each occupy one position.
Reported figures
- Earnings per share
- $-0.13
What stood out
-
Revenue and EPS missed consensus
Second-quarter revenue was $0, below the $618,180 consensus estimate, while diluted EPS was -$0.13 versus the -$0.11 estimate.
-
Quarterly loss widened
Net loss widened to $46.6 million in Q2 2026, indicating continued substantial operating investment in the clinical pipeline.
-
Clinical safety progress
TSHA-102 dosing progressed across 33 patients, with no severe treatment-related serious adverse events or dose-limiting toxicities reported.
-
Financing extends cash runway
The company completed a $230.0 million financing, extending expected cash runway into 2H 2028.
-
SEC investigation terminated
The SEC notified Taysha in June 2026 that it was terminating its investigation and did not intend to recommend enforcement actions.
-
Controls remained effective
Management reported that disclosure controls and procedures were effective as of June 30, 2026, and that there were no material changes to internal control over financial reporting during the quarter.
What to watch
-
No current product revenue
The company reported $0 of Q2 revenue and a diluted loss of -$0.13 per share, underscoring dependence on future product development and commercialization rather than current operating revenue.
-
High cash burn and losses
Net loss reached $46.6 million in Q2 2026, increasing the funding required to advance clinical and regulatory programs despite the $230.0 million financing.
-
Derivative litigation remains unresolved
Two putative stockholder derivative actions filed in January 2024 and April 2024 remain described in the filing; the complaints seek unspecified damages and the company has recorded no liability because potential losses cannot be reasonably estimated.
-
Residual legal and regulatory exposure
Although the SEC investigation was terminated in June 2026, the company continues to face potential litigation and regulatory costs; the filing states that the investigation involved subpoenas issued in late 2024 relating to the August 2023 Private Placement and certain public offerings.
-
Milestone execution risk
The $230.0 million financing is expected to provide runway only into 2H 2028, while management is targeting REVEAL six-month interim topline data and FDA BLA-pathway feedback in 1H 2027, leaving execution and development milestones ahead.
Management's outlook
No numeric financial guidance was provided. Management expects REVEAL six-month interim topline data and FDA feedback on the BLA submission pathway in 1H 2027; the $230.0 million financing is expected to extend cash runway into 2H 2028.
Earlier filings 4
10-K · March 19, 2026
Taysha (TSHA) is a clinical-stage gene therapy company focused on TSHA-102 for Rett syndrome; the company reports strong early clinical readthrough with 12 patients dosed in Part A and positive milestone gains in the…
10-Q · November 4, 2025
Taysha reported Q3 2025 net loss of $32,733 (vs $25,524 in Q3 2024) and revenue of $0 (vs $1,788 in Q3 2024). Cash increased materially to $297,344 as of September 30, 2025 following the May 2025 offering (net proceeds…
10-Q · May 15, 2025
Taysha reported Q1 revenue of $2.302M and GAAP net loss of $21.529M (EPS $(0.08)). Revenue declined versus the prior-year quarter ($3.411M in Q1 2024) while operating loss improved modestly (loss from operations…
This is our reading of a public filing, not the filing itself. Analysis can contain errors; check the source document for full context.